{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-25-000017","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.033604+00:00","generated_at":"2026-05-25T13:57:19.775589+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Evolus reports record Q4 2024 revenue $79.0M (+30% YoY); achieves full-year profitability ahead of expectations","bullets":["Record Q4 revenue $79.0M (+30% YoY); full-year $266.3M (+32% YoY).","GAAP op loss improved to $2.3M Q4; non-GAAP op income $6.7M Q4 and $0.3M full year (profitability ahead of schedule).","Evolysse FDA approval Feb 2025; launch Q2 2025; expected 8-10% of 2025 revenue.","2025 revenue guidance $345-355M (30-33% growth); expects positive non-GAAP op income for full year.","Added ~2,900 new accounts in 2024; total >15,300 accounts; over 50% US account penetration."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-25-000017","json":"https://secwatch.observer/filing/0001570562-25-000017.json","markdown":"https://secwatch.observer/filing/0001570562-25-000017.md","text":"https://secwatch.observer/filing/0001570562-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000017/0001570562-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000017/eols-20250304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T13:57:19.775589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}